# A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

> **NCT04070313** · PHASE2 · TERMINATED · sponsor: **TTY Biopharm** · enrollment: 36 (actual)

## Conditions studied

- Resected Pancreatic Cancer
- Pancreatic Cancer
- Adjuvant Chemotherapy

## Interventions

- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT04070313
- **Lead sponsor:** TTY Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-11
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Study treatment is to use TS-1 (mono-chemotherapy agent) in adjuvant setting for pancreatic cancer, which may be less clinical benefit compared to combination therapy according to current trend at investigators' discretion.
- **Last updated:** 2021-12-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04070313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04070313, "A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04070313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*